Sidley is advising Arvelle Therapeutics, a Swiss-based biopharmaceutical company focused on bringing innovative treatments to patients suffering from central nervous system disorders, on its sale to Angelini Pharma for a total cash consideration of up to US$960 million. Angelini Pharma entered into a sale and purchase agreement with Arvelle Therapeutics’ shareholders on January 4, 2021. Completion of the transaction is subject to customary closing conditions. Subject to completion, and following regulatory approval, Angelini will pay an aggregate consideration of US$610 million in cash. Subsequently, and subject to cenobamate achieving certain revenue targets, a further US$350 million will be paid. To view the article, please click here.